Resource Logo
Business Wire

Research and Markets: What Do Patients Think of Pharma's HIV/AIDS R&D? Study Features 20 Pharma Companies and 32 Biotech Companies




 

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fc5cb0cf/what_do_patients_t) has announced the addition of the "What Do Patients Think of Pharma's HIV/AIDS R&D?" report to their offering.

In 2011, two important events occurred in the world of research into HIV/AIDS treatment. Firstly, as a response to the continued rise in the global numbers of people living with HIV/AIDS, the United Nations issued a June 2011 political declaration aimed at intensifying the efforts of researchers to find new ways to tackle HIV/AIDS with affordable treatments. The UN drive has been welcomed by NGOs, scientists, and industry from all over the world.

Secondly, in July 2011, the Geneva-based International Aids Society (IAS) announced a global scientific strategy, Towards an HIV Cure, that intends to define scientific priorities which must be addressed by future research to tackle HIV persistence in patients undergoing antiretroviral therapy. The IAS hopes that the new strategy will contribute to the establishment of an international research alliance, and/or the expansion and global coordination of existing consortia towards an HIV cure. More than 40 stakeholders and top scientists are working on the strategy.

Some 180 groups representing the interests of people and patients with HIV/AIDS and/or sexually-transmitted diseases (STDs) responded to a first part of the online study. These 180 groups offered comments on three subjects:

(i) How familiar they are with pharma (large) and biotech (small) companies.

(ii) With which companies they partner.

Senior executives of 50 major HIV/AIDS patient groups from around the world assess the quality of the HIV/AIDS R&D conducted by the 20 main pharmaceutical companies in the field. These assessments allow the companies to be ranked according to seven indicators of effective R&D.

180 patient groups with an interest in HIV/AIDS also comment on their familiarity, and partnerships, with the 20 pharma companies and 32 biotech companies listed in this report.

For more information visit http://www.researchandmarkets.com/research/fc5cb0cf/what_do_patients_t

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): 353-1-481-1716
Sector: Pharmaceuticals



 


Copyright © 2012 -Business Wire, Publisher. All rights reserved to Business Wire.Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. Business Wire.

Information in this article was accurate in April 17, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.